The three major Hong Kong stock indices weakened throughout the week of September 7–11, 2026, with the Hang Seng Index down 3.30%, the Hang Seng TECH Index down 5.45% and the Hang Seng China Enterprises Index down 3.61%. while average daily turnover was about HKD 209.6 billion and southbound net buying totalled about HKD 20.1 billion. The Stock Connect eligible securities list adjustment took effect on September 7, with 54 stocks added and 15 removed, and BIDU-W was formally included in Stock Connect, with Citi expecting it to attract about USD 6 billion (about HKD 47 billion) in net new southbound capital over the next 2 to 4 months.
On 14 September 2026, ADICON HOLDINGS (09860.HK) published its 2026 interim report, with revenue of RMB 1,284.8 million for the six months ended 30 June 2026, up 1.1% year on year; gross profit of RMB 487.1 million, up 7.2%, at a 37.9% gross margin; profit for the period of RMB 35.3 million, up 23.4%, of which RMB 32.0 million was attributable to owners of the parent, with basic earnings per share of RMB 0.04; cash and cash equivalents of RMB 870.9 million as at 30 June 2026; and no interim dividend declared.
On 14 September 2026, JINCHUAN INTL (02362.HK) published its 2026 interim report, with revenue of USD 460.2 million for the six months ended 30 June 2026, up 152% year on year; gross profit of USD 167.5 million, profit for the period of USD 61.0 million and profit attributable to shareholders of USD 47.8 million; 36,083 tonnes of copper and 349 tonnes of cobalt sold during the period; bank balances and cash of USD 257.4 million and a gearing ratio of 41.3% as at 30 June 2026; and no interim dividend declared.
On 14 September 2026, IMPACT THERAP-B (07630.HK) published its 2026 interim report, with revenue of RMB 105.2 million for the six months ended 30 June 2026, up 316.8% year on year, including Senaparib sales in China of RMB 70.4 million, up 877.8%; gross profit of RMB 95.5 million at a 90.8% gross margin; loss of RMB 90.8 million, narrowing 29.5%, and adjusted net loss of RMB 20.9 million, narrowing 62.6%; cash and financial assets totalled RMB 1,065.4 million as at 30 June 2026, and no interim dividend was declared.
On 14 September 2026, INSILICO (03696.HK) announced that Mr. Zavoronkovs, chairman of the Board, executive director, chief executive officer and single largest shareholder of the Company, acquired 113,500 ordinary shares in on-market transactions with his personal funds during the period from 4 to 7 September 2026, and is entitled to exercise voting rights over 46,757,000 shares, or approximately 8.02% of the total issued share capital, immediately following the purchase; the purchase was the first tranche under the shareholding increase plan announced on 4 September 2026.
On 13 September 2026, RoboTechnik Intelligent Technology Co., Ltd. published a PHIP on the website of the Stock Exchange seeking the listing of its H shares on the Main Board, with Huatai Financial Holdings (Hong Kong) Limited, Citigroup Global Markets Asia Limited and Orient Capital (Hong Kong) Limited as joint sponsors; the filing shows revenue of RMB 1,569.6 million, RMB 1,104.2 million and RMB 948.8 million for 2023, 2024 and 2025 respectively, an annual loss of RMB 45.0 million in 2025, and revenue of RMB 198.6 million and a loss of RMB 74.7 million for the four months ended 30 April 2026; by 2025 revenue the Company ranked first globally in silicon photonics smart manufacturing equipment with a 20.5% market share. The Company's A shares are listed on the ChiNext Market of the Shenzhen Stock Exchange (300757.SZ).
On 13 September 2026, Hunan Junxin Environmental Protection Co., Ltd. published a PHIP on the website of the Stock Exchange seeking the listing of its H shares on the Main Board, with CICC Hong Kong Securities Limited and CITIC Securities (Hong Kong) Limited as joint sponsors; the filing shows revenue of RMB 1,836.6 million, RMB 2,410.9 million and RMB 2,730.7 million and profit of RMB 652.8 million, RMB 686.2 million and RMB 994.0 million for 2023, 2024 and 2025 respectively, and revenue of RMB 736.4 million and profit of RMB 304.9 million for the three months ended 31 March 2026. The Company's A shares are listed on the ChiNext Market of the Shenzhen Stock Exchange (301109.SZ).
On 13 September 2026, Shenzhen Camsense Technologies Co., Ltd. published a PHIP on the website of the Stock Exchange seeking the listing of its H shares on the Main Board, with CICC Hong Kong Securities Limited and Guosen Securities (HK) Financing Limited as joint sponsors; the filing shows revenue of RMB 332.1 million, RMB 433.3 million and RMB 613.5 million for 2023, 2024 and 2025 respectively, a turnaround to a net profit of RMB 2.2 million in 2025, and revenue of RMB 195.9 million and net profit of RMB 7.8 million for the three months ended 31 March 2026. The PHIP is a draft, and the offer price and the number of offer shares remain to be determined.
On 13 September 2026, Shenzhen Hai Robotics Innovation Group Co., Ltd. published an application proof on the website of the Stock Exchange seeking the listing of its H shares on the Main Board, with Goldman Sachs (Asia) L.L.C. and CITIC Securities (Hong Kong) Limited as joint sponsors; the filing shows 2025 revenue of RMB 2,016.9 million and a gross margin of 31.2%, with the Company ranked as the world's largest ACR solution provider by 2025 revenue and shipment volume with a market share of over 30%, and revenue of RMB 1,118.1 million in the first half of 2026. The application proof is a draft, and the offer price and the number of offer shares remain to be determined.
On 14 September 2026, 160 HEALTH (02656.HK) announced in a voluntary announcement that its domestic subsidiary had completed the delivery of an integrated solution in a total amount of RMB 12.2 million to a big health enterprise focusing on the research and development of smart wearable health devices, and had obtained an acceptance certificate, with the solution comprising a smart health monitoring system, computing power infrastructure and integrated commissioning services; the announcement cautioned that the business remains at an early stage and has not yet formed a scaled or recurring revenue model, and that the order is not a discloseable transaction under Chapter 14 or a connected transaction under Chapter 14A of the Listing Rules.
On 14 September 2026, FORMS SYNTRON (06700.HK) published a prospectus to launch its global offering of H shares at a maximum offer price of HKD 16.00 per H share, comprising 58,961,100 H shares, of which 5,896,200 H shares are under the Hong Kong offering and 53,064,900 H shares under the international offering; based on the maximum offer price, net proceeds after underwriting fees and estimated expenses are estimated at approximately HKD 869.4 million. The offer price is expected to be determined on or around 18 September 2026, and the H shares are expected to commence trading on the Stock Exchange at 9:00 a.m. on 22 September 2026.
On 14 September 2026, LIGENT TECHNOLOGIES (09856.HK) published a prospectus to launch its global offering at an offer price of HKD 32.96 per share, comprising 172,014,700 offer shares subject to the over-allotment option, of which 17,201,500 shares are under the Hong Kong offering and 154,813,200 shares under the international offering; net proceeds are estimated at approximately HKD 5,445.3 million after estimated expenses, or approximately HKD 6,295.7 million if the over-allotment option is exercised in full. The shares are expected to commence trading on the Main Board of the Stock Exchange at 9:00 a.m. on 22 September 2026.
On 11 September 2026, CLARITY MEDICAL (01406.HK) announced the key findings of the forensic investigation into the IPO allegations and the independent internal control review, with the forensic investigation report by Grant Thornton finding insufficient evidence that the Group's profitability had been manipulated for the purpose of a false listing; the Group has adopted and implemented all recommended remediation measures. Trading in the Company's shares has been suspended since 15 April 2025 and will continue to be suspended.
On 11 September 2026, TRIGIANT (01300.HK) announced that its indirect wholly-owned subsidiary has succeeded in the bid on the Chongqing Assets and Equity Exchange for the acquisition of 100% equity interests in Qinghai Zhongli Optical Fibre Technology Co., Ltd. from the Vendor at a consideration of RMB455 million (equivalent to approximately HK$526 million); the Target Company is principally engaged in the production and sales of optical fibre preforms, optical fibres and optical fibre connectors.
On 11 September 2026, ASR Microelectronics (688220.SH) submitted a listing application to HKEX. The Company is a platform-based fabless semiconductor company which has built an integrated technology platform underpinned by multi-standard cellular baseband technology, AI computing technology and complex SoC design capabilities; according to Frost & Sullivan, it ranked first globally in the cellular connectivity chip market by shipment volume in 2025, with a market share of 37.8%.
On 11 September 2026, TIGERMED (03347.HK) announced that its actual controllers Ye Xiaoping and Cao Xiaochun received on the same day a warning letter and a Prior Notice of Administrative Penalty (Zhe Zheng Fa Zi [2026] No. 21) issued by the Zhejiang Regional Office of the CSRC, and that the two are proposed to be given a warning and fined RMB 1 million in aggregate for suspected violations in information disclosure relating to changes in shareholding.
